

OBJECTIVE

- Niemann-Pick disease Type C (NPC) is a rare, progressive, neurodegenerative disease with no FDA-approved treatments and persisting unmet medical need.
- Arimoclomol is an investigational orally available small molecule for the treatment of
- Rare disease data are sparse and data collection opportunities limited.
- Randomized controlled trials remain the data collection gold standard, however, real -world data (RWD) can contribute additional and important insights as increasingly recognized by regulatory authorities.
- RWD collected in an ongoing protocol-driven Expanded Access Program (EAP) aim to expand the understanding of NPC, including in populations not previously studied in controlled clinical trials.
- Furthermore, data collected will be transferred (with consent) to the International Niemann-Pick Disease Registry (INPDR) to contribute to a single world-wide source of NPC RWD.

METHODS AND RESULTS

Design and setup

- For the data collection specifications of the arimoclomol EAP, we cooperated with INPDR - a disease-specific worldwide registry which aims to support diagnosis, improve clinical care and advance research in NPC (Figure 1 and 2).
- Through the EAP, early access to arimoclomol is provided for a group of NPC patients, neither eligible for nor able to participate in clinical trials (**Table 1**) and who, in the opinion and clinical judgement of the treating physician, may benefit from treatment with arimoclomol prior to its potential marketing authorization.
- The arimoclomol EAP was designed to provide expanded access to patients in 7 countries, with 44 sites globally.
- RWD are primarily collected in the US and the focus of this poster is therefore on the US arimoclomol EAP (clinicaltrials.gov ID: NCT04316637).
- The 15-site US arimoclomol EAP was designed to maximize data capture in this rare disease population, while decreasing burden of participation on patients, caregivers, and staff through inclusion of broad geographic site representation (Figure 3), telemedicine consultations, direct-to-patient shipment, and local laboratories for blood tests (Figure 4).

Table 1: EAP Eligibility and Ineligibility Criteria

Eligibility Criteria	Ineligibility Criteria	
Confirmed NPC diagnosis and at least 1 neurological	Severe liver insufficiency	
symptom	Renal insufficiency	
Age ≥ 2 years	Known or suspected allergy or intolerance to arimoclomol or its constituents Pregnancy, planning to become pregnant (during the EAP) or currently breastfeeding	
Permanent US resident		
If taking miglustat (Zavesca®), the patient must have been on the target dose for the past 6 weeks		
Sexually active females of child-bearing potential must agree to use highly effective contraception	Plans for treatment with other investigational drug during the EAP or in the 4 weeks prior to arimoclomol treatment start	
Confirmed negative pregnancy test for sexually active		
females	The patient is either eligible and able to participate in	
Sexually active male patients with female partners of child- bearing potential agree to use a condom in addition to birth	or is currently participating in an active interventional clinical trial within the indication	
control used by their partners	 The patient, in the opinion of the clinician, is unable to comply with the treatment or has a medical condition that would potentially increase the risk to the patient by participation The patient has a medical condition which hinders the clinician's assessment of arimoclomol safety and efficacy (e.g. certain epileptic conditions or severe cataplexy) 	
If history of seizures, the condition must be adequately controlled, i.e., seizure activity must be stable, and patient must be on stable dose and regimen of antiepileptic		
medication during 1 month prior to screening		
Written informed consent (patient or parent/guardian)		
For participants in CT-ORZY-NPC-002 clinical trial: The treating physician confirms a positive benefit risk assessment for the patient at end of trial.		

Real World Data Collection in Niemann-Pick Disease Type C Data from Expanded Access Program with Arimoclomol Elizabeth M. Berry-Kravis¹, Daniel Gallo², Kristin Pagano², Ronan O'Reilly², Conan Donnelly³ ¹Rush University Medical Center, Chicago, IL, USA, ²Zevra Therapeutics, Orlando, FL, USA, ³INPDR, Washington, Tyne & Weir NE37 2SQ, UK

52nd Annual Child Neurology Society Meeting, Vancouver, BC, Canada, October 4-7, 2023




Table 2: Mandatory (A) and Optional (B) Data Collection

A Data Type	Data Element / Description	B Data Type	Data Element / Description	
Enrollment	Country, Site, RWD Consent, Gender, Year of Birth	Demography	Age of diagnosis, Ethnicity.	
Demography	Race, Height, Weight	NPC Diagnosis	Age when Diagnostic Tests Performed, Name of Labs where tests are performed, Dates of Tests.	
NPC diagnosis	DNA Testing for NPC1, NPC2 mutations and further genetic variants, Cytochemical and Oxysterol testing (if performed)	Physical Examination	Examination of the patient's general physical condition.	
		NPC Disease History	Age at First observed for Visceral Abnormalities, Neurological Development and Impairments	
Treatment Initiation	Patient Age, Treatment Initiation Date, Initial Dose	INFO DISCUSCI HISTORY	and other relevant NPC diseases (If present)	
	T attent / ge , freatment initiation Date, initial Dose	Medical History	Details of any non-NPC related significant diseases	
Repeating Arimoclomol Treatment	Height, Weight, Dosing Strength Dates and adjustments	5-domain NPCCSS	A disease-specific and validated measure of disease progression, consisting of the five clinically most relevant domains (cognition, speech, swallow, fine motor skills and ambulation) (Table 3).	
Laboratory data	Results Units and Ranges			
Safety Serious Adverse Events and non-serious AEs considered related to arimoclomol		Concomitant Medication	Specification of any medication taken by the patient during the last six weeks prior to enrollment. New and changed medications.	

METHODS AND RESULTS						
Mandatory and Optional Data Collection						
inical care is maintained with clinical assessments at haseline an						

- Routine clinical care is maintained, with clinical assessments at baseline and months 1, 4, 7 and 12. Beyond this, data are collected at routine follow-up visits.
- Training is provided to ensure consistent and reliable scoring of the NPC Clinical Severity Scale (NPCCSS) (Table 3).
- Effectiveness and safety data are collected through a secure online portal.
- Limited mandatory assessments are required for participation in the EAP (Table 2, A) while some RWD collection is optional (Table 2, B).
- 98% percent of patients have consented to RWD collection in the US (data on file).
- Of these, 96.3% contribute physician-reported 5-domain NPCCSS scores. • 60.9% currently contribute a minimum of 1 year 5-domain NPCCSS follow-up
- Capture of patient-reported outcomes is supported, but limited data have been captured, possibly due to lack of mobile application data capture capability.
- The EAP has provided arimoclomol expanded access to adult and pediatric patients, yielding maximum longitudinal data spanning greater than 2 years.

Domain	Ambulation	Fine Motor Skills	Swallow	Cognition	Speech
Scoring	0: Normal	0: Normal	0: Normal, no dysphagia	0: Normal	0: Normal
	1: Clumsy	1: Slight dysmetria/ dystonia (independent manipulation)	 1: Cough while eating: <u>Intermittent dysphagia:</u> +1: w/Liquids^a 	 Mild learning delay, grade appropriate for age Moderate learning de- 	 1: Mild dysarthria (easily understood) 2: Severe dysarthria
	2: Ataxic unassisted gait or not walking by 18 months	2: Mild dysmetria/Dystonia (requires little to no as- sistance, able to feed self without difficulty)	+1: w/Solids ^a <u>Dysphagia:</u> +2: w/Liquids ^a +2: w/Solids ^a	lay, individualized curric- ulum or modified work setting	
	4: Assisted ambulation or not walking by 24 months	4: Moderate dysmetria/ dystonia (limited fine motor skills, difficulty feeding self)	4: Nasogastric tube or gastric tube for supple- mental feeding	4: Severe delay/plateau, no longer in school or no longer able to work, some loss of cognitive function	3: Non-verbal/functional communication skills for needs
	5: Wheelchair dependent	 5: Severe dysmetria/ Dystonia (gross motor limitation, requires as- sistance for selfcare ac- tivities) 	gastric tube feeding on- ly	Ŭ	5: Minimal communication

^a Score is additive (to "cough while eating"-score of 1) in subdomains 'intermittent dysphagia' and 'dysphagia' and can range from 0-5. Example: For intermittent dysphagia w/ solids and dysphagia w/ liquids a score of 4 applies (1+1+2)). ^b higher score = more severe clinical impairment

CONCLUSIONS

- This collection of RWD from NPC patients participating in a global EAP will expand the understanding of this rare disease and the effectiveness and safety of arimoclomol.
- Addition of these RWD to the INPDR may help guide future clinical management and development of treatment options.

Acknowledgements:

The successful design and setup of this EAP is the result of a collaborative effort involving many stakeholders, sites and staff including the INPDR.

A special thanks to Dr. Christina Guldberg for sharing her valuable insights and learnings in relation to this EAP.

Disclosures:

E. M. Berry-Kravis has worked under consultancy agreements for Zevra Therapeutics. D.Gallo is an employee of Zevra Therapeutics, K. Pagano and R.O'Reilly are in-house consultants with Zevra Therapeutics.

Poster prepared by Lene S Schmidt from Pharma IT Aps., funded by Zevra Therapeutics.